Home / Pharma News

Pharma News

Ireland’s IPHA hits back at high drug prices claim

The Irish Pharmaceutical Healthcare Association (IPHA) has hit back at statements from the European Commission’s (EC’s) troika that drug prices in the country are unjustifiably high.

Health Canada approves generic oxycodone despite fears of abuse

Canada’s drug regulator Health Canada has approved a generic non-crush resistant form of oxycodone, despite the fact that US officials have been urging their Canadian counterpart to ban such formulation of the powerful painkiller.

Ireland high drug prices cannot be justified

The European Commission’s troika mission to Ireland has told Government TDs (Members of Parliament) that the cost of pharmaceutical drugs in the country cannot be justified. Drug prices in the country have been found to be at least three times more expensive than in the UK.

EMA launches public catalogue of drug shortages

The European Medicines Agency (EMA) announced on 4 November 2013 the launch of its public catalogue on supply shortages of drugs.

FDA announces two actions to combat drug shortages

The US Food and Drug Administration (FDA) announced on 31 October 2013 that it is taking two important actions to further enhance the agency’s ongoing efforts to prevent and resolve drug shortages.

Australia should not copy New Zealand’s drug pricing system

Australia should resist ongoing pressure to adopt a New Zealand-style model of medicines funding, according to Medicines Australia, a group that represents originator manufacturers.

US state introduces law to allow meds to be bought over Internet

On 9 October 2013, the US state of Maine introduced a law allowing its residents to purchase foreign prescription drugs over the Internet.

India approves Mylan’s purchase of Agila

Generics giant Mylan announced on 3 September 2013 that its proposed acquisition of generics injectables maker Agila Specialties (Agila) from Strides Arcolab for Rs 5,168-crore (US$1.6 billion) had been cleared by the Indian Government.

Johnson & Johnson warns of shortages of cancer drug Doxil

Janssen Pharmaceutical Companies (Janssen), a division of healthcare giant Johnson & Johnson, has warned of impending shortages of its ovarian cancer drug Doxil (doxorubicin).

Sandoz launches new device for its biosimilar somatropin

Sandoz, the generic drug division of Swiss drug giant Novartis, announced on 23 September 2013 the launch of a new delivery device for its biosimilar somatropin product (Omnitrope) in the UK.